Hutchison Medipharma International News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

Chi-Med Initiates Rolling Submission of NDA to U S FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

TMCnet News Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors [December 28, 2020] Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors â Company plans to complete rolling submission in the first half ofÂ 2021Â â â The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefitÂ ratioÂ â â The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefitÂ ratioÂ â

Mark leeZhou yiFreddy crossley atholl tweedieMarek kaniaBen atwell alex shawAnnie chengHutchison china meditech limited chiDrug administrationSurufatinib developmentExchange commissionCommittee for medicinal products humanHutchison medipharma internationalEuropean medicines agencyNational medical products administration of chinaVirtual congressMed initiates rolling submission

Chi-Med Initiates Rolling Submission of NDA to U S FDA for Surufatinib for the Treatment of

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of . Hutchison China MediTech LimitedDecember 28, 2020 GMT – Company plans to complete rolling submission in the first half of 2021 – – The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio – – The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefit ratio –

Mark leeZhou yiFreddy crossley atholl tweedieMarek kaniaBen atwell alex shawAnnie chengHutchison china meditech limited chiDrug administrationSurufatinib developmentExchange commissionCommittee for medicinal products humanHutchison medipharma internationalEuropean medicines agencyNational medical products administration of chinaVirtual congressChina meditech limited